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Introduction
For decades, the concept of nuclear receptors (NRs) was only linked to chemical changes with physiological effects. However, considering the fundamental nature of these receptors, including their mode of genomic interactions, their recognition of specific chemical ligands, and their transcriptional control, they could not be characterized by simple chemical changes. This eventually led to more detailed analyses of the properties of these receptors. In brief, NRs were first investigated with respect to their hormonal effects, which led to the characterization of these receptors as transcription factors that regulate genes encoding steroid receptors in the mid1980s. With respect to the mechanism by which these receptors function via ligands, it was proposed that if the cDNA encoding the receptor was sufficient to reconstitute a hormone response, then expression plasmids with the cDNA can be cotransfected with a hormone-responsive reporter gene to make a highly defined twocomponent regulatory switch. The switch is flipped "on" by hormone binding, resulting in a powerful transcriptional response that allows the rapid analysis of the DNA-and ligand-binding domains as well as ligand and target gene specificity. This idea was quite versatile as a cell-based approach to study transcription and rapidly became the mainstay of nearly every molecular biology laboratory. Since then, many studies have examined NRs, which are considered a superfamily consisting of a number of ligand-activated receptors involved in various physiological activities. These receptors function either alone as homodimers or as heterodimers with other NRs [1, 2] .
Retinoid X receptor (RXR) is a member of the NR superfamily and works as a permissive or nonpermissive heterodimeric partner with other NRs [3] . The RXR, which includes three types (a, b, and g), has well-established roles in inflammation and immunity [4e6] . For instance, many studies have indicated that RXRa is involved in inflammation, especially in myeloid cells [7, 8] . The most common ligand for RXR receptors is 9-cis-retinoic acid, and other fatty acids and natural compounds, termed "rexinoids" [9, 10] , also act as ligands.
The physiological response of cells toward a foreign invader terminates in a phenomenon referred to as inflammation, which is an integrated release of factors that combat foreign invasion by the secretion of antiinflammatory chemicals. In addition to the release of antiinflammatory factors, many proinflammatory chemicals that serve to aggravate inflammation are released [11] . If inflammation is not controlled, the balance between proinflammatory and antiinflammatory factors would be disturbed, leading to the further secretion of proinflammatory factors, genomic dysregulation, DNA damage, epigenetic instability, and extreme alterations in intracellular signaling pathways [12] . Therefore, the timely alleviation of inflammation is needed to avoid these detrimental effects.
Panax ginseng Meyer has been a widely used herbal supplement in the Korean peninsula for centuries. Previous studies, including many recent studies, have reported the health-enhancing effects of ginseng, particularly in alleviating major diseases [13, 14] .
Ginseng is available in many forms in the Korean peninsula, from whole root extracts to single ginsenosides in the form of tablets and drinks. Ginsenosides are the single compounds present in whole ginseng extracts; they are responsible for ginseng activity. The individual effects of numerous ginsenosides on health have been reported [15, 16] . Rg3-enriched red ginseng extract (Rg3-RGE) has been studied extensively owing to its vasodilating, antiinflammatory, and antioxidant properties [17] . In this study, we found for the first time that the antiinflammatory effects of Rg3-RGE are mediated by the NR heterodimer RXRa and peroxisome-proliferating receptor g (RXRaePPARg).
Materials and methods

Reagents
Dulbecco's modified Eagle's medium (DMEM) (Daegu, Korea), fetal bovine serum (FBS) (WelGene Co., Gyeongsan, Korea), streptomycin and penicillin (Lonza, Walkersville, MD, USA), TRIzol reagent (Invitrogen, Carlsbad, CA, USA), oligo-dT (Bioneer, Daejeon, Korea), lipopolysaccharide (LPS) (Escherichia coli 055:B5), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (Sigma, St. Louis MO, USA) were used in the study. All other reagents and chemicals were obtained from Sigma Aldrich.
Sample preparation
Rg3-RGE used in this study was prepared with the extraction of red ginseng root/stem (25:75) with distilled water and later with 55% of ethanol. Thereafter, multiple extractions were carried out again with water and ethanol to prepare a concentrated extract. Then, the constituents in the extract were analyzed by HPLC. The HPLC results revealed the following concentrations of ginsenosides in Rg3-RGE extract. Rb1 ¼ 3.86 mg/g, 20(S)-Rg3 ¼ 44.91 mg/g, Rc ¼ 1.20 mg/g, Rb2 ¼ 1.53 mg/g, Rd ¼ 1.60 mg/g, Rf ¼ 1.28 mg/g, Rh1 ¼ 3.71 mg/g, 20(S)-Rg2 ¼ 3.55 mg/g, and 20(R)-Rg3 ¼ 6.78 mg/g out of 67.41 mg/g of total contents.
Cell culture
The murine macrophage cell line RAW 264.7 obtained from the American Type Culture Collection was cultured in DMEM supplemented with 8% FBS and 100 IU/mL penicillin and 100 mg/mL streptomycin sulfate. The cells were incubated at 37 C in a humidified atmosphere with 5% CO 2 .
Nitric oxide assay
Nitric oxide (NO) was measured based on the Griess reaction assay. Briefly, RAW 264.7 cells were seeded in 96-well plates and incubated with or without LPS (0.1 mg/mL) in the absence or presence of Rg3-RGE at the indicated concentrations with various NR agonists and antagonists for 18 hours. The cell culture supernatants (100 mL) were mixed with Griess reagent (0.2% naphthylethylenediamine dihydrochloride and 2% sulfanilamide in 5% phosphoric acid) in ddH 2 O at equal volumes and incubated for 5 minutes at room temperature. The absorbance in each well was then analyzed at 540 nm using a microplate reader (VersaMax Microplate Reader; Molecular Devices, Sunnyvale, CA, USA).
Cell viability (MTT) assay
To determine the cytotoxic effects of multiple treatment groups, cell viability assays were performed using MTT reagent, which was added to the culture medium at a final concentration of 0.1 mg/mL. After 4 hours of incubation at 37 C in 5% CO 2 , the resulting violetcolored crystals were dissolved in 100 mL of dimethyl sulfoxide, and absorbance was measured at 560 nm.
2.6. Overexpression and siRNA transfection of RXRa, PPARg, and liver X receptor beta RAW 264.7 cells were cultured in DMEM in 24-well plates with 10% FBS and 1% penicillin/streptomycin at 37 C humidified 5% CO 2 . For the overexpression of RXRa, three concentrations of the RXRa plasmid (extracted using Midiprep; Qiagen, Hilden, Germany) were transfected into RAW cells in antibiotic-free media using Lipofectamine 2000 (Invitrogen). Transfection was performed according to the manufacturer's instructions. For the transfection of siRNA for RXRa, PPARg, and liver X receptor beta (LXRb), briefly, RAW 264.7 cells were cultured in 24-well plates in DMEM without penicillin/streptomycin. siRNAs were used at 100 nM to transfect cells using Lipofectamine in antibiotic-free media for 5 hours.
2.7. RNA extraction and quantitative reverse transcription polymerase chain reaction RAW 264.7 cells were treated with RXRa plasmid in various concentrations for overexpression and with siRXRa for silencing the expression. Total RNA was extracted using TRIzol reagent following the manufacturer's instructions. RNA was then annealed using oligo-dT for 10 minutes at 70 C, cooled for 5 minutes on ice, reverse transcribed using a reverse transcriptase premix (Bioneer) in a 20-mL reaction mixture, and reacted for 90 minutes at 42.5 C using a thermal cycler (Biometra GmbH, Gottingen, Germany). The reactions were terminated at 95 C for 5 minutes to inactivate the reverse transcriptase. Quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed using aliquots of cDNA obtained from the aforementioned reaction, and the PCR products were separated by electrophoresis on a 1% agarose gel. cDNA was subjected to real-time PCR using SYBR Green chromophore. The gel was stained with ethidium bromide and visualized using Eagle Eye image analysis software (Stratagene, LA Jolla, CA, USA). The intensity of each band was normalized against the intensity of the corresponding GAPDH band. Sequences of primers used for PCR are given in Table 1 .
Nuclear hormone receptorebinding assay
A receptor-binding ligand assay was performed by Lead Hunter Discovery Services (DiscoverX Corporation, Fremont, CA, USA). Briefly, according to the service protocol, PathHunter nuclear hormone receptor cell lines were expanded from freezer stocks according to standard procedures. Cells were seeded in a total volume of 20 mL in white-walled, 384-well microplates and incubated at 37 C for the appropriate time before testing. Assay media had charcoal dextranefiltered serum to reduce the level of hormones. For agonist determination, cells were incubated with the sample to induce a response. An intermediate dilution of sample stocks was performed to generate a 5Â sample in the assay buffer. Then, 5 mL of the 5Â sample was added to cells and incubated at 37 C or room temperature for 3e16 hours. The final assay vehicle concentration was 1%. Compound activity was analyzed using chemical and biological information systems (CBIS) data analysis suite (ChemInnovation, San Diego, CA, USA). For agonist mode assays, the percentage activity was calculated using the following formula: Activity (%) ¼ 100 Â (mean relative luminescence units (RLU) of the test sample e mean RLU of the vehicle control)/(mean MAX control ligand e mean RLU of the vehicle control).
Molecular docking
To investigate the binding mode of the ginsenoside Rg3 (GRg3) to RXRa and PPARg as potential NRs, a molecular docking analysis was performed (protein data bank (PDB) codes: RXRa, 5ec9; for PPARg, 2q8s). The conformation of G-Rg3 was generated using a conformational search (ZINC95098804) against the ZINC docking database, University of California, San Francisco (UCSF) [18] . The cocrystalized structures were prepared using UCSF Chimera (Chimera, Version 1.12, RBVI, San 3D, three-dimensional; G-Rg3, ginsenoside Rg3, NHR, nuclear hormone receptor; PPARg, peroxisome-proliferating receptor g; Rg3-RGE, Rg3-enriched red ginseng extract; RXRa, retinoid X receptor a.
Francisco, CA, USA) and iGEMDOCK (Version 2.1; NCTU, Hsinchu City, Taiwan). Molecular docking was performed using iGEM-DOCK with accurate docking mode. The best docked poses were further analyzed, and three-dimensional (3D) structures were prepared using UCSF Chimera.
Statistical analysis
Results are presented as means AE standard deviation (SD). Oneway analysis of variance and Dunnett's tests were used for the statistical evaluation of the data. Differences with ***p < 0.001 were considered significant.
Results
Rg3-RGE is a ligand for RXRa-PPARg
NRs are ligand-dependent transcription factors that regulate diverse aspects of development and homeostasis. Several members of the NR superfamily have recently emerged as key regulators of inflammation and immune responses [19] . As shown in Table 2 , our results revealed that Rg3-RGE has a maximum receptor-binding affinity for the NRs RXRa and PPARg. The binding efficacies of Rg3-RGE with RXRa and 9-cis retinoic acid (used as a reference compound for NR studies) are shown in Figs. 1A and 1B. Because G- G-Rg3, ginsenoside Rg3; PPARg, peroxisome-proliferating receptor g; RA, retinoic acid; RXRa, retinoid X receptor. LXRb, liver X receptor beta; PPARg, peroxisome-proliferating receptor g; RXRa, retinoid X receptor a.
Rg3 was the most abundant compound in Rg3-RGE (data not shown), we used molecular docking analysis to determine how and where G-Rg3 interacts with its potent NRs, i.e., RXRa and PPARg. Fig. 1C shows the molecular structure of G-Rg3, and Figs. 1D and 1F show the two-dimensional (2D) molecular structures of G-Rg3 inside the RXRa receptor (indicated by the green chain in Figs. 1D and1E and blue chain in Fig. 1F ). Fig. 1G shows the 3D structure of G-Rg3 in the RXRa receptor. Similarly, Figs. 1H and 1K show the 2D molecular structures of G-Rg3 inside the PPARg receptor (indicated by a green chain in Figs. 1H and 1I and blue chain in Fig. 1J ). Fig. 1K shows the 3D structure of G-Rg3 in the PPARg receptor. The binding energies of G-Rg3-RXRa and G-Rg3-PPARg according to molecular docking are given in Table 3 . Based on the ligand receptorebinding assay and molecular docking analysis, we determined the effects of the RXRa agonist CD3594 and its specific antagonist HX531 on NO production in the presence and absence of Rg3-RGE. Our results showed that CD3594 exhibited the same NO-inhibitory effect as Rg3-RGE; however, HX531 blocked NO production, as shown in Figs. 2A and 2B . Furthermore, the receptor binding and docking analyses confirmed that Rg3-RGE exhibits strong binding to PPARg, and NRs commonly act in combination as either homo or heterodimers [20, 21] ; therefore, as shown in Figs. 2C and 2D, Rg3-RGE, similar to the effects of the RXRa agonist and antagonist, influenced NO production in the presence of a PPARg agonist (rosiglitazone) and antagonist (GW9662) in a dose-dependent manner. Previous studies have shown that RXRa also forms heterodimers with LXRb to elicit antiinflammatory effects [22e27]. Therefore, we examined the NO level of GW3965 (LXRb agonist) and found that it was not synergistically inhibited or enhanced in the presence of Rg3-RGE (Fig. 2E) . NO production levels for all three NR agonists and antagonists and their cotreatments are shown in Figs. 3Ae3D. As shown in Fig. 3B , treatment with the RXRa agonist (CD3594) inhibited NO production, comparable to the recovery of NO by cotreatment with its antagonist (HX531). Moreover, the PPARg agonist (rosiglitazone) decreased NO production, and this effect was comparable to the reversal of NO production by the RXRa antagonist (HX531). As shown in Fig. 3C , treatment with Rg3-RGE inhibited NO production, and this effect was comparable to the recovery of NO by cotreatment with the PPARg antagonist (GW9662). The PPARg agonist (rosiglitazone) decreased NO production, comparable to the reversal of NO production by its own antagonist (GW9662). Interestingly, the RXRa agonist (CD3594) inhibited NO production, whereas the RXRa agonist (CD3594) along with the PPARg antagonist (GW9662) significantly reversed NO production. These results suggest that RXRa-PPARg function as heterodimers. Furthermore, as shown in Fig. 3D , treatment with Rg3-RGE inhibited NO production, and cotreatment with the LXRb antagonist (GSK2033) recovered NO production. The LXRb agonist (GW3965) decreased NO production, comparable to the reversal of NO production by its own antagonist (GSK2033). There was no cross-reactivity with the LXRb agonist and antagonist. No cytotoxicity was observed for any of the aforementioned treatment groups (data not shown).
Effects of the overexpression and knockdown of RXRa on NO production
To further confirm that the effects of Rg3-RGE are mediated by RXRa-PPARg, we transfected macrophages with an RXRa plasmid and investigated the effects of Rg3-RGE and both RXRa and PPARg agonists on NO production. The overexpression of RXRa was verified ( LXRb, liver X receptor beta; PPARg, peroxisome-proliferating receptor g; Rg3-RGE, Rg3-enriched red ginseng extract; RXRa, retinoid X receptor a.
significantly in the presence of both the RXRa and PPARg agonists, but not the LXRb agonist. No cytotoxicity was observed for the treatment groups. Moreover, the knockdown of RXRa caused a reversion in NO production in the presence of Rg3-RGE and CD3594 (Fig. 4D) . Transfection of siPPARg and siLXRb also displayed similar results to those for siRXRa in the presence of Rg3-RGE and their respective agonists. This experiment was repeated using the antagonists for all three NRs, and the RXRa antagonist and PPARg antagonist both significantly inhibited NO production, but the LXRb antagonist did not have any such effect (Fig. 4E) . The validation of siRXRa was confirmed by real-time and RT-PCR (Fig. 4F). 3.3. Effects of PPARa and RXRa-PPARg heterodimeric agonists on RAW 264.7 cells in the presence of Rg3-RGE As previously indicated, within the RXR family of proteins, RXRa possesses the greatest binding affinity for Rg3-RGE. Similar to the RXR family of proteins, PPAR has three subtypes (PPARa, b, and g), which vary with respect to their biological functions. For instance, several studies have investigated the role of PPARg in inflammation [28, 29] . Given that PPARg may be associated with other members in its own family, we investigated the effect of a PPARa agonist (WY14643) in the presence and absence of Rg3-RGE and an RXRa agonist on PPARg-associated NO production. As shown in Fig. 5A , WY14643 did not have a synergistic effect on the inhibition of NO production, and separately, Rg-RGE and its agonist (CD3594) significantly decreased NO production. Moreover, we also investigated the effect of LG 100754, a RXRa-PPARg heterodimeric agonist, in the presence and absence of Rg3-RGE, CD3594, and rosiglitazone to confirm that Rg3-RGE signaling is mediated by RXRa-PPARg. As shown in Fig. 5B , the RXRa agonist (CD3594) suppressed NO slightly, but in combination with Rg3-RGE, it synergistically inhibited NO production. The same results were observed for the cotreatment of Rg3-RGE with an RXRa-PPARg heterodimeric agonist (LG 100754). Interestingly, the RXRa agonist (CD3594) and RXRa-PPARg heterodimeric agonist (LG 100754) synergistically inhibited NO production. Moreover, the PPARg agonist (rosiglitazone) and RXRa-PPARg heterodimeric agonist (LG 100754) also synergistically inhibited NO production, proving that the effects of Rg3-RGE are mediated by the RXRa-PPARg heterodimer. The inhibition of NO by the PPARa agonist (WY14643) and RXRa-PPARg heterodimeric agonist (LG 100754) is shown in Figs. 5C and 5D. No cytotoxicity was observed for any of the aforementioned treatment groups (data not shown). LXRb, liver X receptor beta; PPARg, peroxisome-proliferating receptor g; Rg3-RGE, Rg3-enriched red ginseng extract; RT-PCR, quantitative reverse transcription polymerase chain reaction; RXRa, retinoid X receptor a.
Discussion
The ginsenoside Rg3 has been studied extensively owing to its beneficial effects on many pathological conditions. For example, Yoon et al reported that Rg3 suppresses the production of inducible NO synthase (iNOS) via the regulation of the S-nitrosylation of the NLRP3 inflammasome [30] . Moreover, Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2eassoci-ated X proteins [31] . In addition, Rg3 induces apoptosis in various cancer cell lines, e.g., cisplatin-resistant bladder tumor cells, human osteosarcoma cells, human ovarian cancer cells, and many more [32e34]. We found evidence for potent disease-reducing effects of Rg3; the ginseng extract used in our study was enriched for this ginsenoside. Moreover, we unraveled the strong antiinflammatory effects of Rg3-RGE (data not shown). The main purpose of our study was to identify the receptor that was involved in the antiinflammatory effects of Rg3-RGE; despite numerous studies of Rg3-RGE, the receptor that is responsible for its mode of action has not been investigated previously.
NRs are a class of cell surface molecules that mediate a variety of functions, from metabolism to immunity and reproduction [35] . Their versatility stems largely from their ability to dimerize with other receptors. RXRs are among the most widely studied NRs as they are involved in inflammation. They commonly interact with members of their own family of proteins or other receptors, including PPARg [20,28,36e40] , LXRb, and several others [23, 27, 36, 41, 42] . Our receptor-binding assay results showed that Rg3-RGE has maximum binding affinity for RXRa but also binds effectively to other subtypes of RXR (data not shown). Molecular docking is a strong structural molecular biology tool for determining the precise ligand compoundebinding mode for 2D and 2D structures. Basically, the major function of docking is to identify the specific site where the compound of interest interacts with its receptor; these analyses provide information about the kind of bonds and binding energies which a receptor has with its compound. This technique is particularly important for the generation of specific gene knockout animal models [43, 44] . Using this technique, we found that G-Rg3 has strong binding sites in the RXRa and PPARg nuclear receptor complex (Figs. 1De1K) . To further support our hypothesis, we performed in vitro analyses to determine whether RXRa and PPARg are involved in the antiinflammatory effects of Rg3-RGE. For this purpose, we selected RXRa-and PPARg-specific agonists and antagonists. Accordingly, we observed the suppression of NO production in response to cotreatment with the RXRa and PPARg agonist and Rg3-RGE (Figs. 2Ae2D) . Moreover, when RXRa was silenced, Rg3-RGE did not reduce NO production. Similar results were observed when using the RXRa-specific antagonist, which did not inhibit NO production (Figs. 4D and 4E) . These results showed that RXRa and PPARg are involved in the antiinflammatory effects of Rg3-RGE in vitro.
RXRa and other NRs typically function with the help of other NRs, prompting us to investigate whether RXRa acts alone or by forming homo or heterodimers when facilitating the effects of Rg3-RGE [45] . Our receptor-binding assay and molecular docking analyses indicated that Rg3-RGE shows good binding affinity to other classes of NRs, i.e., PPARg and LXRb. Using specific agonists and antagonists of these NRs, we found that Rg3-RGE dose-dependently inhibited NO production when it is used in combination with either of these two NRs (Figs. 3Ae3D) . However, differences in NO production were observed when PPARg and LXRb were specifically knocked down. The PPARg agonist and antagonist showed similar results with respect to NO production to those observed using the RXRa agonist and antagonist (Figs. 4De4E) . However, LXRb did not exhibit any specific receptor-mediated activity, especially when LXRb knockdown cells were treated with the LXRb antagonist [ Fig. 4E (third graph in row) ]. Accordingly, we nullified the heterodimerization of RXRa with LXRb and investigated the RXRaPPARg heterodimer. In particular, we evaluated the RXRa-PPARg heterodimeric agonist [46, 47] and found that it significantly suppressed NO production in the presence of Rg3-RGE, the RXRa agonist, and the PPARg agonist. To determine whether PPARg is specifically involved in the functions of RXRa, we examined the PPARg-RXRa heterodimeric-specific agonist (LG100754) and then stimulated with LPS for 18 hours. Cell supernatants were then mixed with equal amounts of Griess reagent, and NO production was measured. Values in bar graph are means AE SD of three independent experiments. ***p < 0.001 was considered significant compared to the indicated groups.
LXRb, liver X receptor beta; PPARg, peroxisome-proliferating receptor g; Rg3-RGE, Rg3-enriched red ginseng extract; RXRa, retinoid X receptor a. effect of the PPARa-specific agonist in the presence of Rg3-RGE and found that it did not synergistically inhibit NO production when compared to the PPARg-specific agonist and the RXRa-PPARg heterodimeric agonist (Figs. 5Ae5B) . A summarized diagrammatic form of our research results is shown in Fig. 6 . Thus, our results clarified for the first time that the strong antiinflammatory effects of Rg3-RGE are mediated by the NRs RXRa and PPARg.
Conclusion
In conclusion, our results demonstrated, for the first time, that the strong antiinflammatory effects of Rg3-RGE are mediated by RXRa-PPARg. Further mechanistic studies, including in vivo studies of the NR molecular mechanisms, may provide additional insight into the functions of Rg3-RGE.
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